Renal function alone is insufficient: use the route-specific matrix with lean body weight, clinical response, interactions, electrolytes and measured concentrations. Digoxin immune Fab is an antidote, not another digoxin formulation. SPS describes when to measure levels, not universal daily laboratory testing.
Before applying: Separate serum concentration monitoring from routine renal/electrolyte checks; the 7-day post-change advice is limited to normal renal function.
Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (3)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
Official source
Digoxin - oral tablets
Product / population
Adult oral maintenance excerpt from label Table 3; no pediatric dosing or loading algorithm.
Renal measure
Label-corrected creatinine clearance to 70 kg or 1.73 m2, plus lean body weight.
Before using this finding
Confirm corrected renal measure, lean weight, route and specimen timing. The complete matrix is a source table, not a patient-specific dose recommendation.
Renal guidance and important limits
Limits that apply to these rows
Adult reference: CrCl in this table is corrected to 70 kg or 1.73 m2, not an interchangeable unindexed clearance. These are maintenance doses, not loading doses.
Renal impairment prolongs steady state and toxicity. Sample just before the next dose or at least 6 hours after dosing. Interpret the result with symptoms, electrolytes and interacting medicines.
Open complete source table: Digoxin oral maintenance matrix - mcg ONCE daily
Display filter only. No dose is selected or calculated. Copy and print retain the complete matrix.
Digoxin oral maintenance matrix - mcg ONCE daily
Corrected CrCl (mL/min)
40 kg lean weight (mcg once daily)
50 kg lean weight (mcg once daily)
60 kg lean weight (mcg once daily)
70 kg lean weight (mcg once daily)
80 kg lean weight (mcg once daily)
90 kg lean weight (mcg once daily)
100 kg lean weight (mcg once daily)
Days to steady state without loading
10
62.5*
125
125
187.5
187.5
187.5
250
19
20
125
125
125
187.5
187.5
250
250
16
30
125
125
187.5
187.5
250
250
312.5
14
40
125
187.5
187.5
250
250
312.5
312.5
13
50
125
187.5
187.5
250
250
312.5
312.5
12
60
125
187.5
250
250
312.5
312.5
375
11
70
187.5
187.5
250
250
312.5
375
375
10
80
187.5
187.5
250
312.5
312.5
375
437.5
9
90
187.5
250
250
312.5
375
437.5
437.5
8
100
187.5
250
312.5
312.5
375
437.5
500
7
Label values assume average body composition; use both corrected CrCl and lean weight. No interpolation, automatic selection or rounding is performed. *62.5 mcg is approximately 30% below calculated dosing; monitor and titrate. Tablet values reflect whole/half-tablet rounding.
Read the retained text before reformatting
Digoxin oral maintenance matrix - mcg ONCE daily
Corrected CrCl (mL/min)
40 kg lean weight (mcg once daily)
50 kg lean weight (mcg once daily)
60 kg lean weight (mcg once daily)
70 kg lean weight (mcg once daily)
80 kg lean weight (mcg once daily)
90 kg lean weight (mcg once daily)
100 kg lean weight (mcg once daily)
Days to steady state without loading
10
62.5*
125
125
187.5
187.5
187.5
250
19
20
125
125
125
187.5
187.5
250
250
16
30
125
125
187.5
187.5
250
250
312.5
14
40
125
187.5
187.5
250
250
312.5
312.5
13
50
125
187.5
187.5
250
250
312.5
312.5
12
60
125
187.5
250
250
312.5
312.5
375
11
70
187.5
187.5
250
250
312.5
375
375
10
80
187.5
187.5
250
312.5
312.5
375
437.5
9
90
187.5
250
250
312.5
375
437.5
437.5
8
100
187.5
250
312.5
312.5
375
437.5
500
7
Label values assume average body composition; use both corrected CrCl and lean weight. No interpolation, automatic selection or rounding is performed. *62.5 mcg is approximately 30% below calculated dosing; monitor and titrate. Tablet values reflect whole/half-tablet rounding.
Adult reference: CrCl in this table is corrected to 70 kg or 1.73 m2, not an interchangeable unindexed clearance. These are maintenance doses, not loading doses.
Renal impairment prolongs steady state and toxicity. Sample just before the next dose or at least 6 hours after dosing. Interpret the result with symptoms, electrolytes and interacting medicines.
Source revision: 6/2024 | Retrieved: 2026-09-10. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
Confirm corrected renal measure, lean weight, route and specimen timing. The complete matrix is a source table, not a patient-specific dose recommendation.
Adult oral maintenance excerpt from label Table 3; no pediatric dosing or loading algorithm.
Renal method: Label-corrected creatinine clearance to 70 kg or 1.73 m2, plus lean body weight. Retrieved: 2026-09-10
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
source scope and renal guidance
Before use: Digoxin - oral tablets
Renal function alone is insufficient: use the route-specific matrix with lean body weight, clinical response, interactions, electrolytes and measured concentrations. Digoxin immune Fab is an antidote, not another digoxin formulation. SPS describes when to measure levels, not universal daily laboratory testing.
How to use this: Separate serum concentration monitoring from routine renal/electrolyte checks; the 7-day post-change advice is limited to normal renal function.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source
Digoxin - oral tablets
Adult oral maintenance excerpt from label Table 3; no pediatric dosing or loading algorithm.
Method: Label-corrected creatinine clearance to 70 kg or 1.73 m2, plus lean body weight.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
DailyMed / NLM exact product labeling · Adult oral maintenance excerpt from label Table 3; no pediatric dosing or loading algorithm.
Renal method: Label-corrected creatinine clearance to 70 kg or 1.73 m2, plus lean body weight. Source date: 6/2024 Retrieved: 2026-09-10
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
Confirm corrected renal measure, lean weight, route and specimen timing. The complete matrix is a source table, not a patient-specific dose recommendation.
Selected source sections stored locally. Not a complete monograph or independent clinical approval.
Renal guidance and important limits
Limits that apply to these rows
Adult reference: CrCl in this table is corrected to 70 kg or 1.73 m2, not an interchangeable unindexed clearance. These are maintenance doses, not loading doses.
Renal impairment prolongs steady state and toxicity. Sample just before the next dose or at least 6 hours after dosing. Interpret the result with symptoms, electrolytes and interacting medicines.
Open complete source table: Digoxin oral maintenance matrix - mcg ONCE daily
Display filter only. No dose is selected or calculated. Copy and print retain the complete matrix.
Digoxin oral maintenance matrix - mcg ONCE daily
Corrected CrCl (mL/min)
40 kg lean weight (mcg once daily)
50 kg lean weight (mcg once daily)
60 kg lean weight (mcg once daily)
70 kg lean weight (mcg once daily)
80 kg lean weight (mcg once daily)
90 kg lean weight (mcg once daily)
100 kg lean weight (mcg once daily)
Days to steady state without loading
10
62.5*
125
125
187.5
187.5
187.5
250
19
20
125
125
125
187.5
187.5
250
250
16
30
125
125
187.5
187.5
250
250
312.5
14
40
125
187.5
187.5
250
250
312.5
312.5
13
50
125
187.5
187.5
250
250
312.5
312.5
12
60
125
187.5
250
250
312.5
312.5
375
11
70
187.5
187.5
250
250
312.5
375
375
10
80
187.5
187.5
250
312.5
312.5
375
437.5
9
90
187.5
250
250
312.5
375
437.5
437.5
8
100
187.5
250
312.5
312.5
375
437.5
500
7
Label values assume average body composition; use both corrected CrCl and lean weight. No interpolation, automatic selection or rounding is performed. *62.5 mcg is approximately 30% below calculated dosing; monitor and titrate. Tablet values reflect whole/half-tablet rounding.
Read the retained text before reformatting
Digoxin oral maintenance matrix - mcg ONCE daily
Corrected CrCl (mL/min)
40 kg lean weight (mcg once daily)
50 kg lean weight (mcg once daily)
60 kg lean weight (mcg once daily)
70 kg lean weight (mcg once daily)
80 kg lean weight (mcg once daily)
90 kg lean weight (mcg once daily)
100 kg lean weight (mcg once daily)
Days to steady state without loading
10
62.5*
125
125
187.5
187.5
187.5
250
19
20
125
125
125
187.5
187.5
250
250
16
30
125
125
187.5
187.5
250
250
312.5
14
40
125
187.5
187.5
250
250
312.5
312.5
13
50
125
187.5
187.5
250
250
312.5
312.5
12
60
125
187.5
250
250
312.5
312.5
375
11
70
187.5
187.5
250
250
312.5
375
375
10
80
187.5
187.5
250
312.5
312.5
375
437.5
9
90
187.5
250
250
312.5
375
437.5
437.5
8
100
187.5
250
312.5
312.5
375
437.5
500
7
Label values assume average body composition; use both corrected CrCl and lean weight. No interpolation, automatic selection or rounding is performed. *62.5 mcg is approximately 30% below calculated dosing; monitor and titrate. Tablet values reflect whole/half-tablet rounding.
Adult reference: CrCl in this table is corrected to 70 kg or 1.73 m2, not an interchangeable unindexed clearance. These are maintenance doses, not loading doses.
Renal impairment prolongs steady state and toxicity. Sample just before the next dose or at least 6 hours after dosing. Interpret the result with symptoms, electrolytes and interacting medicines.
RDM64-official-digoxin-oral-tablets-8508567622-C1 · Source locator: Sections 2.1, 2.3 Table 3 including footnotes, 2.5-2.6 and 8.6.
Source-specific limits
Adult reference: CrCl in this table is corrected to 70 kg or 1.73 m2, not an interchangeable unindexed clearance. These are maintenance doses, not loading doses.
Renal impairment prolongs steady state and toxicity. Sample just before the next dose or at least 6 hours after dosing. Interpret the result with symptoms, electrolytes and interacting medicines.
GlobalRPh-hosted RX List · Adult oral digoxin; selected maintenance and monitoring text.
Renal method: Corrected CrCl and lean body weight, not CrCl alone. Source date: Revision not established in selected retrieval Retrieved: 2026-09-10
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
Use exact-formulation official labeling for loading; do not combine the mirror loading interval with another source regimen.
Selected source sections stored locally. Not a complete monograph or independent clinical approval.
Renal guidance and important limits
Limits that apply to these rows
This mirror has a separate oral matrix. It is not an injection or immune-Fab protocol.
Its oral loading paragraph uses a 4-8-hour interval; the selected Hikma label uses 6-8 hours. Loading was not imported as a renal algorithm.
Oral digoxin - what the renal source requires
Decision
Source-specific instruction
Maintenance selection
Use the source matrix with corrected clearance and lean body weight; renal impairment requires smaller maintenance doses.
Monitoring
Interpret drug levels with clinical response, electrolytes, interacting medicines and longer renal steady-state time.
Read the retained text before reformatting
Oral digoxin - what the renal source requires
Decision
Source-specific instruction
Maintenance selection
Use the source matrix with corrected clearance and lean body weight; renal impairment requires smaller maintenance doses.
Monitoring
Interpret drug levels with clinical response, electrolytes, interacting medicines and longer renal steady-state time.
This mirror has a separate oral matrix. It is not an injection or immune-Fab protocol.
Its oral loading paragraph uses a 4-8-hour interval; the selected Hikma label uses 6-8 hours. Loading was not imported as a renal algorithm.
NHS Specialist Pharmacy Service · UK professional monitoring guidance; not a US product-label dose table.
Renal method: Serum creatinine for CrCl, electrolytes and clinical monitoring. Source date: 27 December 2023 Retrieved: 2026-09-10
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
Separate serum concentration monitoring from routine renal/electrolyte checks; the 7-day post-change advice is limited to normal renal function.
Selected source sections stored locally. Not a complete monograph or independent clinical approval.
Renal guidance and important limits
Limits that apply to these rows
Routine serum digoxin measurement is not recommended. Baseline and ongoing renal/electrolyte assessment still matter, with more frequent monitoring in elderly patients or renal impairment.
A concentration within a stated range does not exclude toxicity. Thyroid status, potassium, magnesium, calcium and clinical signs influence interpretation.
When to assess digoxin concentrations
Situation
Source-specific instruction
Sample timing
At least 6 hours after a dose, ideally 8-12 hours.
Dose change with NORMAL renal function
The source suggests a level 7 days after the change.
Deteriorating renal function, interactions or suspected toxicity
Consider a level and individualized closer review; do not apply the normal-renal 7-day timing automatically.
Read the retained text before reformatting
When to assess digoxin concentrations
Situation
Source-specific instruction
Sample timing
At least 6 hours after a dose, ideally 8-12 hours.
Dose change with NORMAL renal function
The source suggests a level 7 days after the change.
Deteriorating renal function, interactions or suspected toxicity
Consider a level and individualized closer review; do not apply the normal-renal 7-day timing automatically.
Routine serum digoxin measurement is not recommended. Baseline and ongoing renal/electrolyte assessment still matter, with more frequent monitoring in elderly patients or renal impairment.
A concentration within a stated range does not exclude toxicity. Thyroid status, potassium, magnesium, calcium and clinical signs influence interpretation.
RDM64-professional-digoxin-oral-tablets-b592f6593b-C1 · Source locator: Before starting; ongoing once stable; when to take a level; abnormal results.
Source-specific limits
Routine serum digoxin measurement is not recommended. Baseline and ongoing renal/electrolyte assessment still matter, with more frequent monitoring in elderly patients or renal impairment.
A concentration within a stated range does not exclude toxicity. Thyroid status, potassium, magnesium, calcium and clinical signs influence interpretation.
Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.